Ligand id: 7739
Name: alectinib
View more information in the IUPHAR Pharmacology Education Project: alectinib
|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2015), EMA (2017), Japan (unknown)) |
IUPAC Name ![]() |
9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile |
International Nonproprietary Names ![]() |
|
INN number | INN |
9699 | alectinib |
Synonyms ![]() |
AF802 | Alecensa® | CH5424802 |
Comments |
Alectinib is a second generation ALK inhibitor. It was developed to inhibit the expression of the mutated ALK gene that causes growth of some non-small cell lung cancers, in patients whose cancer has become resistant to the older ALK inhibitor, crizotinib [2,5]. However, additional mutations may develop which confer alecitinib resistance [1]. Cells harbouring these novel mutations are reported to be sensitive to ceritinib and other next-generation ALK tyrosine kinase inhibitors [1]. The identification of the mechanisms by which acquired tumour resistance occurs highlights the importance of being able to use the correct drug for the correct patient to maximise the clinical benefit [4] The design and synthesis of alectinib (CH5424802) is described in [2]. |
Database Links ![]() |
|
CAS Registry No. | 1256580-46-7 |
ChEMBL Ligand | CHEMBL1738797 |
GtoPdb PubChem SID | 223366072 |
PubChem CID | 49806720 |
RCSB PDB Ligand | EMH |
Search Google for chemical match using the InChIKey | KDGFLJKFZUIJMX-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | KDGFLJKFZUIJMX |
Search PubMed clinical trials | alectinib |
Search PubMed titles | alectinib |
Search PubMed titles/abstracts | alectinib |
Search UniChem for chemical match using the InChIKey | KDGFLJKFZUIJMX-UHFFFAOYSA-N |
Search UniChem for chemicals with the same backbone | KDGFLJKFZUIJMX |